|A division of Multicorp International, Inc.
|MultiCorp International, Inc. is focused on bringing the patented migraine medicine the company acquired a 70% stake in back in October
2014. Over the past 16 months we have contracted with several companies to further the drug to gain feedback from the FDA.
The company received a report back on our queries to the FDA and this has laid the groundwork for the company to go to Proof of
Concept clinical trials in an emergency room setting. This 4-Arm study will compare our medicine to the current one(s) in the marketplace.
The current U.S. market for migraine medications stand at over $800 Million and we’re fairly confident that since the medication we are
proposing, based on our patent, could achieve at least a 10-15% share of this market which translate to between $80-$120 Million. This is a
conservative estimate due to the near zero side effects the drug has shown in the past having been dispensed to over 1200 patients over
the last 11 years in a clinical setting. The company has high expectations this drug will become the norm in bringing relief to the migraine
sufferers here in the U.S. and eventually to the global market.
As we progress in developing this study and beginning the process, the company will look to partner with a larger pharmaceutical
company that will give us the distribution needed to bring the product to market, possible sooner than our goal of 2 years.
|Migraine is an extraordinarily common disease that affects 38 million men, women and children in the United States. Almost everyone
either knows someone who has suffered from migraine, or has struggled with migraine themselves.
Many people do not realize how serious and debilitating migraine can be. In addition to attack-related disability, migraine interferes with a
sufferer's ability to function in everyday life, whether that is going to school or work, caring for family or enjoying social activities.
Migraine is not just a bad headache.
For many sufferers, migraine is a chronic disease that significantly diminishes their quality of life.
Migraine is a public health issue with serious social and economic repercussions.
Source - Migraine Research Foundation